Academic Personnel Short Profile / Short CV

University:	UNIC Athens
Surname:	Argiris
Name:	Athanassios
Rank/Position:	Professor
Faculty:	Medical School
Department:	Basic and Clinical Sciences -TRF
Scientific Domain: *	Oncology

** Field of Specialization*

Academic qualifications (list by highest qualification)

Qualification	Year	Awarding Institution	Department	Thesis title (Optional Entry)
Doctoral Thesis	2004	National and Kapodistrian University of Athens	Medical School	
Medical School Diploma	1990	National and Kapodistrian University of Athens	Medical School	

Employment history in Academic Institutions/Research Centers – List by the three (3) most recent

Period of employment		Employer	Location	Position
From	To			
2026	Present	UNIC Athens	Athens, Greece	Professor
2016	2026	Thomas Jefferson University	Philadelphia, USA	Professor

Ref. Number	Year	Title	Other authors	Journal and Citation
1	2026	"Neoadjuvant nivolumab plus carboplatin and paclitaxel in	Zinner RG, Mastrolonardo EV, Johnson JM, Nunes K, Llerena	Clin Cancer Res. 2025 Dec 12. doi:

		patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trial".	P, Elliott Z, Tuluc M, Curry JM, Fundakowski CE, Yampolsky A, Goldman R, Solomides CC, Gargano SM, Naringrekar H, Harshyne L, Poller D, Leiby BE, Bar-Ad V, Axelrod R, Argiris A, Luginbuhl AJ, Cognetti DM	10.1158/1078-0432.CCR-25-2807. Epub ahead of print. PMID: 41385730
2	2026	"Different Pattern of Treatment Failure After Chemoradiation Between p16+ and p16- Patients Affected by Oropharyngeal Carcinoma".	Gili R, Bossi P, Lalli L, Licitra LFL, Maddalo M, Bacigalupo A, Belgioia L, Cacicedo J, Facchinetti N, Castano AG, Oliva M, Bonomo P, Sanguineti G, Franco P, Argiris A, Psyrri A, Orlandi E	Head Neck. 2026 Mar 5. doi: 10.1002/hed.70222. Epub ahead of print. PMID: 41786623.
3	2025	"Extracellular matrix-myCAF signatures correlate with resistance to neoadjuvant aPD-L1 immune checkpoint inhibition with durvalumab + metformin in HPV+ HNSCC"	Llerena P, Samarah H, Nunes K, Lin Z, Bridgham K, Tekumalla S, Jain A, Harshyne L, Shukla SK, Vathiotis I, Tuluc M, Gargano S, Eisenbrey JR, Keith S, Cognetti DM, Bar-Ad VC, Luginbuhl AJ, Axelrod R, Vadigepalli R, Yang H, Whitaker-Menezes D, Roche M, Mahoney MG, Argiris A, Solomides C, Johnson JM, Barbirou M, Miller A, South AP, Mitra R, Linnenbach AJ, Martinez-Outschoorn U, Curry JM	Clin Cancer Res. 2025 Sep 11. doi: 10.1158/1078-0432.CCR-25-1098. Epub ahead of print. PMID: 40932382.
4	2025	"*Nasopharyngeal Cancer Portal Group of Investigators. A multicenter retrospective analysis of recurrent/metastatic nasopharyngeal cancer from non-endemic areas: Results in the pre-immunotherapy era*"	Alberti A, Gurizzan C, Resteghini C, Trama A, Bernasconi A, Grisanti S, Zamparini M, Mohamad I, Linares Galiana I, Ozyar E, Franco P, Vecchio S, Bonomo P, Cirauqui B, El-Sherify M,	Eur J Cancer. 2025 Oct 16;229:115749. doi: 10.1016/j.ejca.2025.115749. Epub 2025 Sep 2. PMID: 40912138.

			Ursino S, Argiris A, Pan J, Wittekindt C, D'Angelo E, Costa L, Buglione M, Johnson JM, Airoldi M, Mesia R, Licitra L, Orlandi E, Bossi P	
5	2019	*"Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer".*	Argiris A, Li S, Savvides P, Ohr JP, Gilbert J, Levine MA, Chakravarti A, Haigentz M Jr, Saba NF, Ikpeazu CV, Schneider CJ, Pinto HA, Forastiere AA, Burtness B	**J Clin Oncol 2019 Oct 16:JCO1900555. doi: 10.1200/JCO.19.00555. [Epub ahead of print] 37;34:3266-3274**
6	2013	*"Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial"*	Argiris A, Ghebremichael, M, Gilbert, J, Lee J, Sachidanandam K, Kolesar JM, Burtness B, A. Forastiere A	**J Clin Oncol. 2013 Apr 10;31(11):1405-14**
7	2013	*"Cetuximab and bevacizumab: preclinical data and phase II trial in patients with recurrent or metastatic head and neck cancer"*	Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gooding W, Blumenschein Jr GR, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S	**Ann Oncol 2013 Jan;24(1):220-5**
8	2010	*"Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer"*	Argiris A, Heron DE, Smith R, Gibson MK, Lai SY, Kim S, Branstetter BF, Posluszny D, Seethala R, Gooding W, Grandis JR, Johnson JT, Ferris RL	**J Clin Oncol 2010;28:5294-300**
9	2008	"*Head and neck cancer*"	Argiris A, Karamouzis M, Raben D, Ferris R	**Lancet 2008;371:1695-709**
10	2004	*"Prognostic factors and long-term survivorship in patients with recurrent or metastatic head and neck cancer: an analysis of two Eastern Cooperative Oncology*	Argiris A, Li Y, Forastiere A	**Cancer 2004;101:2222-9**

		Group randomized trials"		

Exhibitions (where applicable). List the five (5) more recent and other five (5) selected. (max total 10)					
Ref. Number	**Date**	**Topic**	**International / Local**	**Location***	**Role in Exhibition**
1					
2					
3					
4					
5					
6					
7					
8					
9					
10					

**Specify venue, geographic location etc*

Research Projects. List the five (5) more recent and other five (5) selected (max total 10)				
Ref. Number	**Date**	**Title**	**Funded by**	**Project Role***
1	01/09/12 – 31/8/14	EGFR antisense DNA added to cetuximab and radiotherapy for head and neck cancer *R21 CA130241*	NIH/NCI	PI
2				
3				
4				
5				
6				
7				
8				
9				
10				

**Project Role: i.e. Scientific/Project Coordinator, Research Team Member, Researcher, Assistant Researcher, other*

Academic Consulting Services and/or Participation in Councils / Boards/ Editorial Committees. List the five (5) more recent (Optional Entry)				
Ref. Number	**Period**	**Organization**	**Title of Position or Service**	**Key Activities**
1				
2				
3				
4				
5				

Awards / International Recognition (where applicable). List the five (5) more recent and other five (5) selected. (max total 10) (Optional Entry)			
Ref. Number	**Date**	**Title**	**Awarded by:**
1	2009	ECOG Research and Education Young Investigator Award	Eastern Cooperative Oncology Group (ECOG)
2	2000	Young Investigator Scholar Award for Clinical/Translational Research	American Association for Cancer Research
3			
4			
5			
6			
7			
8			
9			
10			

Other Achievements. List the five (5) more recent and other five (5) selected. (max total 10) (Optional Entry)			
Ref. Number	**Date**	**Title**	**Key Activities:**
1			
2			
3			
4			
5			
6			
7			
8			
9			
10			